Researchers have unveiled powerful new tools and molecules to accelerate drug discovery. Harvard Medical School scientists developed PDGrapher, an AI platform that predicts combinatorial targets to reverse disease states in cells, advancing precision therapeutics beyond single-protein approaches. Concurrently, Chu et al. introduced DEFUSE, a high-throughput screen for discovering small molecule degraders of SKP2, a cancer oncoprotein. Additionally, Padarn Therapeutics and Ohio State have reported novel inhibitors targeting CDK2 and bacterial topoisomerase II respectively, expanding treatment options for cancer and infections.